| Ashley L Holland, DO | |
|
1400 Bellinger St, Eau Claire, WI 54703 | |
| (715) 838-5222 | |
| Not Available |
| Full Name | Ashley L Holland |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 11 Years |
| Location | 1400 Bellinger St, Eau Claire, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205272200 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 66033 (Minnesota) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 71517 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System Eau Claire Hospital | Eau claire, WI | Hospital |
| Mayo Clinic Health System Chippewa Valley | Bloomer, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-northwest Wisconsin Region Inc | 4385553627 | 623 |
News Archive
A large-scale survey of African-American men and women found that those who rarely or never exercised had about twice the odds of abusing alcohol than those who exercised frequently, a finding that could have implications across all groups.
The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Children with bipolar I disorder have significantly poorer cognitive functioning than those with bipolar II disorder, research shows.
Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235588831 PECOS PAC ID: 4385553627 Enrollment ID: O20161109002075 |
News Archive
A large-scale survey of African-American men and women found that those who rarely or never exercised had about twice the odds of abusing alcohol than those who exercised frequently, a finding that could have implications across all groups.
The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Children with bipolar I disorder have significantly poorer cognitive functioning than those with bipolar II disorder, research shows.
Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ashley L Holland, DO 200 1st St Sw, Rochester, MN 55905-0001 Ph: (715) 838-5222 | Ashley L Holland, DO 1400 Bellinger St, Eau Claire, WI 54703 Ph: (715) 838-5222 |
News Archive
A large-scale survey of African-American men and women found that those who rarely or never exercised had about twice the odds of abusing alcohol than those who exercised frequently, a finding that could have implications across all groups.
The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Children with bipolar I disorder have significantly poorer cognitive functioning than those with bipolar II disorder, research shows.
Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727.
› Verified 4 days ago
David Andrew Nye, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Shana L Vifian Ray, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2116 Craig Rd, Eau Claire, WI 54701 Phone: 715-858-4500 | |
Scott T. Schmidt, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Dr. Daniel Ralph Hanson, MD, PHD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1000 Starr Ave, Eau Claire, WI 54703 Phone: 715-858-4300 | |
John Alpheus Bartholow, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Dr. Christina Y Stanga, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Anna W Cothron, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-8222 |